NeuroMab™ Anti-Galanin Antibody,Clone NR946P

Figure 1 depicts the levels of Siglec-7 surface expression and TREM2 surface expression on human dendritic cells following treatment with anti-Siglec-7 antibody 10B5 or an isotype control antibody compared to no antibody control.

Figure 10 depicts results showing that anti-Siglec-7 antibodies 4E3 and 10B5 selectively kill a subset of myeloid-derived suppressor cells (MDSC). Top row: live/dead gate by cell morphology: dead cell gate increased for S7-4E3 and S7-10B5. Middle row: live/dead cells gated using dye: dye high positive cells are dead, dye low cells are alive. Histogram: Displays live/dead cell dyes in a histogram format.

Figure 2 depicts the levels of CD11c surface expression, Siglec-7 surface expression and TREM2 surface expression on human dendritic cells after treatment with anti-Siglec-7 antibody 10B5.

Figure 3 depicts Siglec-7 and CD33 expression in peripheral blood samples from humanized NOG mice 14 days after treatment with anti-Siglec-7 antibodies of the present disclosure.

Figure 4 shows the in vivo reduction of Siglec-7 cell surface levels following antibody treatment in vivo.

Figure 5 depicts a 12-point titration curve showing the half maximal effective concentration (EC50) of Siglec-7 antibodies 4E3 and 10B5 for reducing cell surface expression of Siglec-7

Figure 6 depicts a 12-point titration curve showing the half maximal effective concentration (EC50) of Siglec-7 antibodies 4E3 and 10B5 for reducing cell surface expression of CD11c.

Figure 7 depicts tumor volume following antibody treatment in individual mice transplanted with human immune stem cells. Mice were treated with Keytruda® (pembrolizumab) anti-PD-1 antibody alone or in combination with anti-Siglec-7 antibody 10B5.

Figure 8 depicts mean tumor volume after 28 days of treatment with Keytruda® (pembrolizumab) anti-PD-1 antibody alone or in combination with anti-Siglec-7 antibody 10B5 in mice transplanted with human immune stem cells from human donor 984480112. Mean values for each treatment group are shown. Error bars represent SEM

Figure 9 depicts cells treated with an isotype control antibody (mIgG1 ) compared to anti-Siglec-7 antibody 10B5.

Figure 1 shows the results of the GALR2 filtration assay.

Membrane preparations from A9 cells engineered to overexpress GALR2 were incubated with 125I-labeled human galanin and mouse anti-galanin hybridoma supernatants and harvested onto GF/B Unifilter plates. Twenty-one hybridomas were able to inhibit the binding of human galanin to GALR2.

Figure 2 shows the results of the affinity assay.

Figure 3 shows that administration of anti-galanin antibodies reduces tumor growth in established tumors.